Friday, August 1, 2014

mPEG-PCL for docetaxel delivery to prostate cancer

PolySciTech ( provides a variety of mPEG-PCL copolymers such as polyvivo AK01, AK36 and others. Recently mPEG-PCL polymers were utilized to improve delivery of docetaxel to prostate cancer. Read more: Jin, Ming-ji, Sheng-jun Piao, Tie-xiong Jin, Zhe-hu Jin, Xue-zhe Yin, and Zhong-gao Gao. "Improved anti-tumor efficiency against prostate cancer by docetaxel-loaded PEG-PCL micelles." Journal of Huazhong University of Science and Technology [Medical Sciences] 34 (2014): 66-75.

“Summary: This study primarily focused on the systematic assessment of both in vitro and in vivo anti-tumor effects of docetaxel-loaded polyethylene glycol (PEG)2000-polycaprolactone (PCL)2600 micelles on hormone-refractory prostate cancer (HRPC). By using solvent evaporation method, PEG-PCL was chosen to prepare doxetaxel (DTX)-loaded mPEG-PCL micelles (DTX-PMs), with the purpose of eliminating side effects of the commercial formulation (Tween 80) and prolonging the blood circulation time. The prepared DTX-PMs had an average particle size of 25.19±2.36 nm, a zeta potential of 0.64±0.15 mV, a polydispersity index of 0.56±0.03, a drug loading of (8.72±1.05)%, and an encapsulation efficiency of (98.1±8.4)%. In vitro cytotoxicity studies indicated that DTX-PMs could effectively kill LNCap-C4-2B cells and show a dose- and time-dependent efficacy. The hemolysis test showed that DTX-PMs had less hemocytolysis than the commercial product of Duopafei®. A sustained in vitro release behavior and prolonged circulation time in blood vessels were observed in the DTX-PMs. Furthermore, when compared with Duopafei®, the DTX-PMs dramatically reduced the prostate specific antigen (PSA) level and tumor growth of prostate tumor-bearing nude mice in vivo. In conclusion, the DTX-PMs can lower systemic side effects, improve anti-tumor activity with prolonged blood circulation time, and will bring an alternative to patients with HRPC.”
Post a Comment